Evidence map›Paper›PMID 37097556›Full record

ReviewInfectious diseases and therapy2023

Narrative Review of the Evolution of COVID-19 Vaccination Recommendations in Countries in Latin America, Africa and the Middle East, and Asia.

Júlia Spinardi, Ana Carolina Dantas, Carolina Carballo, Karan Thakkar, Nadine Al Akoury, Moe Hein Kyaw, Graciela Del Carmen Morales Castillo, Amit Srivastava, Marco Aurélio P Sáfadi

Open access · goldAbstract readReview
In one paragraph

Review in Infectious diseases and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Anti-Platelet factor 4 immunothrombosis-not just heparin and vaccine triggers.Research and practice in thrombosis and haemostasis · 2025
    Review
  6. Parental hesitancy for pediatric COVID-19 vaccines in Chile.Therapeutic advances in vaccines and immunotherapy · 2025
    Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Júlia SpinardiVaccine Medical and Scientific Affairs, Pfizer, Rua Alexandre Dumas, 1860, São Paulo, 04717904, Brazil. Julia.Spinardi@pfizer.com.
Ana Carolina DantasVaccines Medical Affairs, Pfizer, São Paulo, Brazil.
Carolina CarballoVaccines Medical Affairs, Pfizer, Buenos Aires, Argentina.
Karan ThakkarVaccines Medical Affairs, Pfizer, Singapore, Singapore.
Nadine Al AkouryVaccine Medical Affairs, Pfizer, Beirut, Lebanon.
Moe Hein KyawVaccines Clinical Epidemiologist Emerging Markets, Pfizer Inc, Collegeville, PA, USA.
Graciela Del Carmen Morales CastilloVaccines Medical Affairs Emerging Markets, Pfizer, San Jose, Costa Rica.
Amit SrivastavaOrbital Therapeutics, Cambridge, MA, 02139, USA.
Marco Aurélio P SáfadiDepartment of Pediatrics, Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.
Pfizer (United States) · USFaculdade de Ciências Médicas da Santa Casa de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid rollout of vaccines to combat the coronavirus disease 2019 (COVID-19) pandemic over the past 2 years has resulted in the use of various vaccine platforms and regional differences in COVID-19 vaccine implementation strategies. The aim of this narrative review was to summarize evolving COVID-19 vaccine recommendations in countries in Latin America, Asia, and Africa and the Middle East across various vaccine platforms, age groups, and specific subpopulations. Nuances in primary and booster vaccination schedules were evaluated, and the preliminary impact of such diverse vaccination strategies are discussed, including key vaccine effectiveness data in the era of Omicron-lineage variants. Primary vaccination rates for included Latin American countries were 71-94% for adults and between 41% and 98% for adolescents and children; rates for first booster in adults were 36-85%. Primary vaccination rates for adults in the included Asian countries ranged from 64% in the Philippines to 98% in Malaysia, with corresponding booster rates varying from 9% in India to 78% in Singapore; for adolescents and children, primary vaccination rates ranged from 29% in the Philippines to 93% in Malaysia. Across included African and Middle Eastern countries, primary vaccination rates in adults varied widely from 32% in South Africa to 99% in the United Arab Emirates; booster rates ranged from 5% in South Africa to 60% in Bahrain. Evidence from the regions studied indicates preference of using an mRNA vaccine as a booster on the basis of safety and effectiveness of observed real-world data, especially during circulation of Omicron lineages. Vaccination against COVID-19 remains of paramount importance to reduce the burden of disease; strategies to overcome vaccine inequity, fatigue, hesitancy, and misinformation and to ensure adequate access and supply are also important.

Indexed as

BoosterCOVID-19HeterologousLatin America, Asia, AfricaMiddle EastRecommendationsVaccination

Identifiers

PMID37097556
PMCPMC10127189
OpenAlexW4366985333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.